STOCK TITAN

Grifols SA - GRFS STOCK NEWS

Welcome to our dedicated news page for Grifols SA (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Grifols SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Grifols SA's position in the market.

Rhea-AI Summary
Grifols has met its enrollment target of 339 patients in the SPARTA clinical trial, which aims to evaluate the efficacy and safety of Grifols' Prolastin®-C in slowing emphysema progression in patients with alpha-1-antitrypsin (AAT) deficiency. The trial is the largest of its kind and will measure the rate of pulmonary-tissue loss over three years. Grifols aims to provide impactful treatment options for alpha-1 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.05%
Tags
partnership
Grifols SA

Nasdaq:GRFS

GRFS Rankings

GRFS Stock Data

5.58B
546.96M
49.36%
0.88%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Spain
Barcelona

About GRFS

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t